Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Evaluating the impact of autoimmune conditions on the outcomes of patients with lymphoma

Posted by on Dec 13, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the impact of autoimmune conditions on the outcomes of patients with lymphoma. This study concluded that these conditions may negatively impact survival outcomes for these patients. Some background Autoimmune conditions are a group of diseases where the immune system attacks the body’s healthy tissues. One...

Read More

Do ACE inhibitors help with anthracycline-induced cardiotoxicity in leukemia and lymphoma?

Posted by on Dec 6, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate if enalapril influences anthracycline-induced cardiotoxicity in children with leukemia and lymphoma. This study concluded that enalapril has a role in reducing anthracycline-induced cardiotoxicity in these patients. Some background Anthracyclines are a class of chemotherapy drugs that can be used for...

Read More

Evaluating brentuximab vedotin plus gemcitabine in children and young adults with relapsed or refractory Hodgkin’s lymphoma

Posted by on Dec 5, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) plus gemcitabine (Gemzar) in children and young adults with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that this combination is safe and shows promising effectiveness in these...

Read More

Evaluating resminostat for patients with relapsed or refractory Hodgkin’s lymphoma

Posted by on Nov 30, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of resminostat in heavily pre-treated patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that resminostat was effective and well-tolerated in these patients. Some background Histone deacetylase inhibitors (HDIs)...

Read More

Whole body vibration during chemotherapy for leukemia and lymphoma

Posted by on Nov 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined the effectiveness of vibration therapy on patients receiving chemotherapy for leukemia and lymphoma. Researchers found that vibration therapy improved daily function in these patients. Some background Exercise is proven to be effective in improving outcomes of patients with cancer. Chemotherapy treatment can make...

Read More

Evaluating intensive first-line treatment for patients with advanced Hodgkin’s lymphoma

Posted by on Nov 27, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with advanced Hodgkin’s lymphoma (HL) who received intensive first-line treatment. This study concluded that intensive first-line treatment with or without radiotherapy led to better long-term outcomes in these patients. Some background For patients with advanced HL,...

Read More

Evaluating survival outcomes after brentuximab vedotin treatment for relapsed or refractory Hodgkin’s lymphoma

Posted by on Nov 22, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the impact of brentuximab vedotin (Adcetris) on the survival of patients with relapsed or refractory (does not respond to treatment) classical Hodgkin’s lymphoma (cHL). This study concluded that brentuximab vedotin significantly improved survival in these patients. Some background Patients with cHL who...

Read More

Outcomes of reduced-intensity conditioning before alloSCT for relapsed or refractory Hodgkin lymphoma

Posted by on Nov 18, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of reduced-intensity conditioning followed by allogeneic stem cell transplantation (alloSCT) in patients with Hodgkin’s lymphoma (HL). This study concluded that this treatment improved survival outcomes in these patients. Some background AlloSCT is an effective therapy for patients with HL who...

Read More

A review of the side-effects of Nivolumab (Opdivo) treatment for Hodgkin Lymphoma.

Posted by on Nov 16, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This paper summarised the side effects associated with the use of nivolumab (Opdivo) for the treatment of Hodgkin Lymphoma. The main finding was that patients treated with nivolumab may experience immune-related side effects. Some background Brentuximab vedotin (Adcetris) and stem cell transplant are often used to treat classical...

Read More

Evaluating brentuximab vedotin after alloSCT in patients with recurrent Hodgkin Lymphoma

Posted by on Nov 8, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of brentuximab vedotin (Adcetris) treatment for patients with relapsed (recurrent) or progressive (tumor grows or spreads) Hodgkin’s lymphoma (HL) after allogeneic (allo) stem cell transplantation (SCT). This study concluded that brentuximab vedotin is safe and effective for these patients. Some...

Read More